Published: 2 September 2015

MARC's Remarks: June 2015 Meeting

Prescriber Update 36(3): 42–43
September 2015

The Medicines Adverse Reactions Committee (MARC) met on 11 June 2015 to discuss a number of medicine-related safety issues.

The MARC discussed the value of consumer reporting of adverse drug reactions and gave advice to Medsafe on how to encourage and promote direct reporting from consumers.

The MARC discussed the risk of bladder cancer with pioglitazone. The MARC considered that the current information in the pioglitazone data sheet was sufficient and concluded that no further action or advice on this risk is required.

The MARC reviewed the available information on statin-associated autoimmune myopathy. An article on the spectrum of muscle effects associated with statin treatment will be included in a future edition of Prescriber Update.

Further information on this meeting can be found on the Medsafe website (